At the concentrations and activities used for diagnostic procedures, technetium ⁹⁹ᵐTc sulesomab does not appear to exert any pharmacodynamic effects.
The antibody (IMMU-MN3) recognizes an antigenic structure shared by a surface glycoprotein (NCA-90) of granulocytes and the tumour marker, carcinoembryonic antigen (CEA).
Pharmacokinetic studies were performed after the intravenous administration of the product. At one hour after infusion, the blood level was 34% of baseline, 17% at four hours and 7% of baseline at 24 hours. The distribution half-life was approximately 1.5 hours; the route of excretion is essentially renal with 41% of the radiolabel excreted in urine over the first 24 hours after administration.
Only very limited nonclinical studies have been performed with either the labeled or unlabeled agent. These revealed no remarkable findings. It should be noted, however, that these studies did not assess genotoxicity, carcinogenic potential, or toxicity to reproduction.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
